Literature DB >> 6471300

Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions.

M Traube, M Hongo, L Magyar, R W McCallum.   

Abstract

We studied the esophageal effects of nifedipine in 20 patients with achalasia (20 mg sublingually) and nine patients with high-amplitude peristaltic esophageal contractions (nutcracker esophagus) (20 mg orally). In patients with achalasia, nifedipine decreased lower esophageal sphincter (LES) pressure by approximately 30%. In ten patients with achalasia, plasma nifedipine concentrations were 45.3 +/- 17.7 and 57.4 +/- 12.8 ng/mL (means +/- SEM) at 30 and 60 minutes, respectively, after drug administration. In patients with nutcracker esophagus, nifedipine decreased LES pressure by approximately 50% and contraction amplitude in the body of the esophagus by approximately 25%. After comparison was made with our previous results in normal subjects, we concluded that (1) nifedipine decreased LES pressure in patients with achalasia to a similar extent to that noted in normal subjects; (2) plasma concentrations measured after 20 mg of nifedipine given sublingually to achalasic patients were similar to those found under similar circumstances in normal subjects; and (3) nifedipine decreased LES pressure and contraction amplitude in patients with nutcracker esophagus to a greater extent than was found in normal subjects. These results suggest that double-blind, placebo-controlled clinical trials of nifedipine in the treatment of achalasia or nutcracker esophagus are indicated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6471300

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  18 in total

Review 1.  An overview of the role of calcium antagonists in the treatment of achalasia and diffuse oesophageal spasm.

Authors:  T P Short; E Thomas
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 2.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 3.  Chest pain of esophageal origin.

Authors:  A K Rustgi; S Chopra
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  On drugs and dilators for achalasia.

Authors:  M Traube
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

Review 6.  Primary oesophageal motility disorders. Current therapeutic concepts.

Authors:  M Traube; R W McCallum
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

Review 7.  The Relevance of Spastic Esophageal Disorders as a Diagnostic Category.

Authors:  Michelle P Clermont; Nitin K Ahuja
Journal:  Curr Gastroenterol Rep       Date:  2018-08-06

Review 8.  Management of spastic disorders of the esophagus.

Authors:  Sabine Roman; Peter J Kahrilas
Journal:  Gastroenterol Clin North Am       Date:  2013-01-04       Impact factor: 3.806

9.  Surgical myotomy in patients with high-amplitude peristaltic esophageal contractions. Manometric and clinical effects.

Authors:  M Traube; V Tummala; A E Baue; R W McCallum
Journal:  Dig Dis Sci       Date:  1987-01       Impact factor: 3.199

Review 10.  A controversy that has been tough to swallow: is the treatment of achalasia now digested?

Authors:  Garrett R Roll; Charlotte Rabl; Ruxandra Ciovica; Sofia Peeva; Guilherme M Campos
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.